LONDON - Astex Therapeutics Ltd. is teaming up with the Multiple Myeloma Research Foundation (MMRF) in an agreement that will see the charity award up to $1 million and provide access to clinicians and patients, to carry out Phase II development of AT7519, a cyclin-dependent kinase inhibitor. (BioWorld International)